Download PDF
Horm Metab Res 2004; 36(5): 261-271
DOI: 10.1055/s-2004-814477
Review
© Georg Thieme Verlag Stuttgart · New York

The Role of the M6P/IGF-II Receptor in Cancer: Tumor Suppression or Garbage Disposal?

C.  D.  Scott1, 2 , S.  M.  Firth1, 2
  • 1Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW 2065
  • 2University of Sydney, NSW 2006, Australia
Further Information

Publication History

Received 1 October 2003

Accepted after Revision 6 January 2004

Publication Date:
24 May 2004 (online)

Also available at
    Permissions and Reprints

Abstract

The mannose 6-phosphate/insulin-like growth factor-II receptor (M6P/IGF-IIR) is an intriguing protein with multiple ligands and multiple functions. Approximately 90 - 95 % of the receptor is located intracellularly, with 5 - 10 % being on the cell surface. It has long been known to play an essential intracellular role in the transport of newly-synthesized lysosomal enzymes from the trans-Golgi network (TGN) to the lysosomes. More recently, however, the loss of this receptor has been described in some tumour types, suggesting that it may play a role in tumour suppression. The focus has therefore shifted to elucidating the role played by the cell surface receptor and its interaction with its diverse ligands in tumour growth and progression. The list of ligands is continuously increasing and includes growth factors such as IGF-II and transforming growth factor β (TGFβ). This review will address the question of whether the M6P/IGF-IIR plays a direct role in tumour suppression or merely plays an indirect role as a transporter for ligands designated for degradation in the lysosomes.

Key words

Mannose 6-phosphate/insulin-like growth factor-II receptor - Tumour suppression

References

  • 1 Dahms N M, Hancock M K. P-type lectins.  Biochim Biophys Acta. 2002;  1572 317-340
    PubMedGoogle Scholar
  • 2 Ghosh P, Dahms N M, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale.  Nature Rev Mol Cell Biol. 2003;  4 202-212
    PubMedGoogle Scholar
  • 3 Devi G R, Byrd J C, Slentz D H, Macdonald R G. An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor.  Mol Endocrinol. 1998;  12 1661-1672
    CrossrefPubMedGoogle Scholar
  • 4 Linnell J, Groeger G, Hassan A B. Real time kinetics of insulin-like growth factor II (IGF-II) interaction with the IGF-II/mannose 6-phosphate receptor: the effects of domain 13 and pH.  J Biol Chem. 2001;  276 23 986-23 991
    PubMedGoogle Scholar
  • 5 Grimme S, Honing S, von Figura K, Schmidt B. Endocytosis of insulin-like growth factor II by a mini-receptor based on repeat 11 of the mannose 6-phosphate/insulin-like growth factor II receptor.  J Biol Chem. 2000;  275 33 697-33 703
    PubMedGoogle Scholar
  • 6 Clairmont K B, Czech M P. Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor.  J Biol Chem. 1991;  266 12 131-12 134
    PubMedGoogle Scholar
  • 7 Tahiri K, Cam L, Desbuquois B, Chauvet G. Processing of the insulin-like growth factor-II-mannose 6-phosphate receptor in isolated liver subcellular fractions.  Biochem Cell Biol. 2001;  79 469-477
    CrossrefPubMedGoogle Scholar
  • 8 Confort C, Rochefort H, Vignon F. IGFs stimulate the release of α1-antichymotrypsin and soluble IGF-II/M6P receptor from MCF7 breast cancer cells.  Endocrinology. 1995;  136 3759-3766
    CrossrefPubMedGoogle Scholar
  • 9 O'Gorman D B, Weiss J, Hettiaratchi A, Firth S M, Scott C D. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo.  Endocrinology. 2002;  143 4287-4294
    CrossrefPubMedGoogle Scholar
  • 10 Xu Y, Papageorgiou A, Polychronakos C. Developmental regulation of the soluble form of insulin-like growth factor-ii mannose 6-phosphate receptor in human serum and amniotic fluid.  J Clin Endocrinol Metab. 1998;  83 437-442
    CrossrefPubMedGoogle Scholar
  • 11 Costello M C, Baxter R C, Scott C D. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay.  J Clin Endocrinol Metab. 1999;  84 611-617
    CrossrefPubMedGoogle Scholar
  • 12 Scott C, Weiss J. Soluble insulin-like growth factor II/mannose 6-phosphate receptor inhibits DNA synthesis in insulin-like growth factor II sensitive cells.  J Cell Physiol. 2000;  182 62-68
    CrossrefPubMedGoogle Scholar
  • 13 Zaina S, Squire S. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms.  J Biol Chem. 1998;  273 28 610-28 616
    PubMedGoogle Scholar
  • 14 De Souza A T, Hankins G R, Washington M K, Orton T C, Jirtle R L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.  Nat Genet. 1995;  11 447-449
    CrossrefPubMedGoogle Scholar
  • 15 Oka Y, Waterland R A, Killian J K, Nolan C M, Jang H S, Tohara K, Sakaguchi S, Yao T, Iwashita A, Yata Y, Takahara T, Sato S, Suzuki K, Masuda T, Jirtle R L. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan.  Hepatology. 2002;  35 1153-1163
    CrossrefPubMedGoogle Scholar
  • 16 Yamada T, De Souza A T, Finkelstein S, Jirtle R L. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis.  Proc Natl Acad Sci USA. 1997;  94 10 351-10 355
    PubMedGoogle Scholar
  • 17 Piao Z, Choi Y, Park C, Lee W J, Park J H, Kim H. Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma.  Cancer Lett. 1997;  120 39-43
    CrossrefPubMedGoogle Scholar
  • 18 Chappell S A, Walsh T, Walker R A, Shaw J A. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas.  Br J Cancer. 1997;  76 1558-1561
    PubMedGoogle Scholar
  • 19 Hankins G R, De Souza A T, Bentley R C, Patel M R, Marks J R, Iglehart J D, Jirtle R L. M6P/IGF2 receptor: A candidate breast-tumor suppressor gene.  Oncogene. 1996;  12 2003-2009
    PubMedGoogle Scholar
  • 20 Leboulleux S, Gaston V, Boulle N, Le Bouc Y, Gicquel C. Loss of heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor locus: a frequent but late event in adrenocortical tumorigenesis.  Eur J Endocrinol. 2001;  144 163-168
    CrossrefPubMedGoogle Scholar
  • 21 Kong F M, Anscher M S, Washington M K, Killian J K, Jirtle R L. M6P/IGF2R is mutated in squamous cell carcinoma of the lung.  Oncogene. 2000;  19 1572-1578
    CrossrefPubMedGoogle Scholar
  • 22 Jamieson T A, Brizel D M, Killian J K, Oka Y, Jang H S, Fu X, Clough R W, Vollmer R T, Anscher M S, Jirtle R L. M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis.  BMC Cancer. 2003;  3 4
    CrossrefPubMedGoogle Scholar
  • 23 De Souza A T, Hankins G R, Washington M K, Fine R L, Orton T C, Jirtle R L. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors.  Oncogene. 1995;  10 1725-1729
    PubMedGoogle Scholar
  • 24 Wada I, Kanada H, Nomura K, Kato Y, Machinami R, Kitagawa T. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan.  Hepatology. 1999;  29 1718-1721
    CrossrefPubMedGoogle Scholar
  • 25 Sue S R, Chari R S, Kong F M, Mills J J, Fine R L, Jirtle R L, Meyers W C. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma.  Ann Surg. 1995;  222 171-178
    PubMedGoogle Scholar
  • 26 Rey J M, Theillet C, Brouillet J P, Rochefort H. Stable amino-acid sequence of the mannose-6-phosphate/insulin-like growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast-cancer cell lines.  Int J Cancer. 2000;  85 466-473
    CrossrefPubMedGoogle Scholar
  • 27 Lemamy G J, Roger P, Mani J C, Robert M, Rochefort H, Brouillet J P. High-affinity antibodies from hen's-egg yolks against human mannose-6-phosphate/insulin-like growth-factor-II receptor (M6P/IGFII-R): characterization and potential use in clinical cancer studies.  Int J Cancer. 1999;  80 896-902
    CrossrefPubMedGoogle Scholar
  • 28 Berthe M L, Esslimani Sahla M, Roger P, Gleizes M, Lemamy G J, Brouillet J P, Rochefort H. Mannose-6-phosphate/insulin-like growth factor-II receptor expression levels during the progression from normal human mammary tissue to invasive breast carcinomas.  Eur J Cancer. 2003;  39 635-642
    CrossrefPubMedGoogle Scholar
  • 29 Byrd J C, Devi G R, de Souza A T, Jirtle R L, MacDonald R G. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations.  J Biol Chem. 1999;  274 24 408-24 416
    PubMedGoogle Scholar
  • 30 Devi G R, de Souza A T, Byrd J C, Jirtle R L, MacDonald R G. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers.  Cancer Res. 1999;  59 4314-4319
    PubMedGoogle Scholar
  • 31 Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability.  Cancer Res. 2002;  62 2447-2454
    PubMedGoogle Scholar
  • 32 Souza R F, Appel R, Yin J, Wang S, Smolinski K N, Abraham J M, Zou T T, Shi Y Q, Lei J, Cottrell J, Cymes K, Biden K, Simms L, Leggett B, Lynch P M, Frazier M, Powell S M, Harpaz N, Sugimura H, Young J, Meltzer S J. Microsatellite instability in the IGF-II receptor gene in gastrointestinal tumours.  Nat Genet. 1996;  14 255-257
    PubMedGoogle Scholar
  • 33 Ouyang H, Shiwaku H O, Hagiwara H, Miura K, Abe T, Kato Y, Ohtani H, Shiiba K, Souza R F, Meltzer S J, Horii A. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum.  Cancer Res. 1997;  57 1851-1854
    PubMedGoogle Scholar
  • 34 Barlow D P, Stoger R, Herrmann B G, Saito K, Schweifer N. The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus.  Nature. 1991;  349 84-87
    CrossrefPubMedGoogle Scholar
  • 35 Lyle R, Watanabe D, te Vruchte D D, Lerchner W, Smrzka O W, Wutz A, Schageman J, Hahner L, Davies C, Barlow D P. The imprinted antisense RNA at the Igf2r locus overlaps but does not imprint Mas1.  Nat Genet. 2000;  25 19-21
    PubMedGoogle Scholar
  • 36 Kalscheuer V M, Mariman E C, Schepens M T, Rehder H, Ropers H H. The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans.  Nat Genet. 1993;  5 74-78
    CrossrefPubMedGoogle Scholar
  • 37 Ogawa O, McNoe L A, Eccles M R, Morison I M, Reeve A E. Human insulin-like growth factor type I and type II receptors are not imprinted.  Hum Mol Genet. 1993;  2 2163-2165
    PubMedGoogle Scholar
  • 38 Oudejans C B, Westerman B, Wouters D, Gooyer S, Leegwater P A, van Wijk I J, Sleutels F. Allelic IGF2R repression does not correlate with expression of antisense RNA in human extraembryonic tissues.  Genomics. 2001;  73 331-337
    CrossrefPubMedGoogle Scholar
  • 39 Xu Y Q, Goodyer C G, Deal C, Polychronakos C. Functional polymorphism in the parental imprinting of the human IGF2R gene.  Biochem Biophys Res Commun. 1993;  197 747-754
    CrossrefPubMedGoogle Scholar
  • 40 Xu Y Q, Grundy P, Polychronakos C. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor.  Oncogene. 1997;  14 1041-1046
    CrossrefPubMedGoogle Scholar
  • 41 Riesewijk A M, Xu Y Q, Schepens M T, Mariman E M, Polychronakos C, Ropers H H, Kalscheuer V M. Absence of an obvious molecular imprinting mechanism in a human fetus with monoallelic IGF2R expression.  Biochem Biophys Res Commun. 1998;  245 272-277
    CrossrefPubMedGoogle Scholar
  • 42 Oates A J, Schumaker L M, Jenkins S B, Pearce A A, DaCosta S A, Arun B, Ellis M J. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene.  Br Cancer Res Treat. 1998;  47 269-281
    PubMedGoogle Scholar
  • 43 Hassan A B. Keys to the hidden treasures of the mannose 6-phosphate/insulin-like growth factor 2 receptor.  Am J Pathol. 2003;  162 3-6
    PubMedGoogle Scholar
  • 44 DaCosta S A, Schumaker L M, Ellis M J. Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate?.  J Mammary Gland Biol Neoplasia. 2000;  5 85-94
    CrossrefPubMedGoogle Scholar
  • 45 Souza R F, Wang S N, Thakar M, Smolinski K N, Yin J, Zou T T, Kong D H, Abraham J M, Toretsky J A, Meltzer S J. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells.  Oncogene. 1999;  18 4063-4068
    CrossrefPubMedGoogle Scholar
  • 46 Lee J, Weiss J, Martin J, Scott C. Increased expression of the mannose-6 phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo.  Int J Cancer. 2003;  107 564-570
    CrossrefPubMedGoogle Scholar
  • 47 Schaffer B S, Lin M F, Byrd J C, Park J H, MacDonald R G. Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells.  Endocrinology. 2003;  144 955-966
    CrossrefPubMedGoogle Scholar
  • 48 O'Gorman D B, Costello M, Weiss J, Firth S M, Scott C D. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells.  Cancer Res. 1999;  59 5692-5694
    PubMedGoogle Scholar
  • 49 Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E. Differential IGF-I receptor signaling and function in ER-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.  Cancer Res. 2001;  61 6747-6754
    PubMedGoogle Scholar
  • 50 Chen Z, Ge Y, Landman N, Kang J X. Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells.  BMC Cancer. 2002;  2 18
    CrossrefPubMedGoogle Scholar
  • 51 Minniti C P, Luan D, O'Grady C, Rosenfeld R G, Oh Y, Helman L J. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype.  Cell Growth Differ. 1995;  6 263-269
    PubMedGoogle Scholar
  • 52 Rainier S, Johnson L A, Dobry C J, Ping A J, Grundy P E, Feinberg A P. Relaxation of imprinted genes in human cancer.  Nature. 1993;  362 747-749
    CrossrefPubMedGoogle Scholar
  • 53 Ogawa O, Eccles M R, Szeto J, McNoe L A, Yun K, Maw M A, Smith P J, Reeve A E. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.  Nature. 1993;  362 749-751
    CrossrefPubMedGoogle Scholar
  • 54 Pedone P V, Tirabosco R, Cavazzana A O, Ungaro P, Basso G, Luksch R, Carli M, Bruni C B, Frunzio R, Riccio A. Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors.  Hum Mol Genet. 1994;  3 1117-1121
    PubMedGoogle Scholar
  • 55 Weksberg R, Shen D R, Fei Y L, Song Q L, Squire J. Disruption of Insulin-Like growth factor 2 imprinting in Beckwith-Wiedemann syndrome.  Nat Genet. 1993;  5 143-150
    CrossrefPubMedGoogle Scholar
  • 56 Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis.  Nature. 1994;  369 414-418
    CrossrefPubMedGoogle Scholar
  • 57 Chen H J, Remmler J, Delaney J C, Messner D J, Lobel P. Mutational analysis of the cation-independent mannose 6-phosphate/ insulin-like growth factor-II receptor: a consensus casein kinase-II site followed by 2 leucines near the carboxyl terminus is important for intracellular targeting of lysosomal enzymes.  J Biol Chem. 1993;  268 22 338-22 346
    PubMedGoogle Scholar
  • 58 Okamoto T, Katuda T, Murayama Y, Ui M, Ogata E, Nishimoto I. A simple structure encodes G protein-activating function of the IGF-II/mannose 6-phosphate receptor.  Cell. 1990;  62 709-717
    CrossrefPubMedGoogle Scholar
  • 59 Okamoto T, Nishimoto I, Murayama Y, Ohkuni Y, Ogata E. Insulin-like growth factor-II/mannose 6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose 6-phosphate, but capable in response to insulin-like growth factor-II.  Biochem Biophys Res Commun. 1990;  168 1201-1210
    CrossrefPubMedGoogle Scholar
  • 60 Korner C, Nurnberg B, Uhde M, Braulke T. Mannose 6-P/IGF-II receptor fails to interact with G-proteins-analysis of mutant cytoplasmic receptor domains.  J Biol Chem. 1995;  270 287-295
    CrossrefPubMedGoogle Scholar
  • 61 Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A.  Oncogene. 2002;  21 8240-8250
    CrossrefPubMedGoogle Scholar
  • 62 Scalia P, Heart E, Comai L, Vigneri R, Sung C K. Regulation of the Akt/glycogen synthase kinase-3 axis by insulin-like growth factor-II via activation of the human insulin receptor isoform-A.  J Cell Biochem. 2001;  82 610-618
    CrossrefPubMedGoogle Scholar
  • 63 Schirmacher P, Held W A, Yang D, Chisari F V, Rustum Y, Rogler C E. Reactivation of Insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth.  Cancer Res. 1992;  52 2549-2556
    PubMedGoogle Scholar
  • 64 Rotsch M, Maasberg M, Erbil C, Jaques G, Worsch U, Havemann K. Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines.  J Cancer Res Clin Oncol. 1992;  118 502-508
    CrossrefPubMedGoogle Scholar
  • 65 Kalli K R, Falowo O I, Bale L K, Zschunke M A, Roche P C, Conover C A. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling.  Endocrinology. 2002;  143 3259-3267
    CrossrefPubMedGoogle Scholar
  • 66 Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine I D, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.  Mol Cell Biol. 1999;  19 3278-3288
    PubMedGoogle Scholar
  • 67 Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer.  J Clin Endocrinol Metab. 2002;  87 245-254
    CrossrefPubMedGoogle Scholar
  • 68 Morrione A, Valentinis B, Xu S Q, Yumet G, Louvi A, Efstratiadis A, Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor.  Proc Natl Acad Sci USA. 1997;  94 3777-3782
    CrossrefPubMedGoogle Scholar
  • 69 LeRoith D, Roberts C T Jr. The insulin-like growth factor system and cancer.  Cancer Lett. 2003;  195 127-137
    CrossrefPubMedGoogle Scholar
  • 70 Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved.  J Biol Chem. 2002;  277 39 684-39 695
    PubMedGoogle Scholar
  • 71 Lau M MH, Stewart C EH, Liu Z Y, Bhatt H, Rotwein P, Stewart C L. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality.  Genes Dev. 1994;  8 2953-2963
    CrossrefPubMedGoogle Scholar
  • 72 Wylie A A, Pulford D J, McVie-Wylie A J, Waterland R A, Evans H K, Chen Y T, Nolan C M, Orton T C, Jirtle R L. Tissue-specific inactivation of murine M6P/IGF2R.  Am J Pathol. 2003;  162 321-328
    PubMedGoogle Scholar
  • 73 Ludwig T, Eggenschwiler J, Fisher P, D'Ercole A J, Davenport M L, Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds.  Dev Biol. 1996;  177 517-535
    CrossrefPubMedGoogle Scholar
  • 74 Moses A C, Nissley S P, Short P A, Rechler M M, White R M, Knight A B, Higa O Z. Increased levels of multiplication-stimulating activity, an insulin-like growth factor, in fetal rat serum.  Proc Natl Acad Sci USA. 1980;  77 3649-3653
    PubMedGoogle Scholar
  • 75 Lund P K, Moats-Staats B M, Hynes M A, Simmons J G, Jansen M, D'Ercole A J, van Wyk J J. Somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues.  J Biol Chem. 1986;  261 14 539-14 544
    PubMedGoogle Scholar
  • 76 Wang S, Souza R F, Kong D, Yin J, Smolinski K N, Zou T T, Frank T, Young J, Flanders K C, Sugimura H, Abraham J M, Meltzer S J. Deficient transforming growth factor-beta1 activation and excessive IGFII expression in IGFII receptor-mutant tumors.  Cancer Res. 1997;  57 2543-2546
    PubMedGoogle Scholar
  • 77 Osipio C, Dorman S, Frankfater A. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors.  Exp Cell Res. 2001;  264 388-396
    CrossrefPubMedGoogle Scholar
  • 78 Butt A J, Firth S M, Baxter R C. The IGF axis and programmed cell death.  Immunol Cell Biol. 1999;  77 256-262
    CrossrefPubMedGoogle Scholar
  • 79 Moorehead R A, Fata J E, Johnson M B, Khokha R. Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice.  Cell Death Differ. 2001;  8 16-29
    CrossrefPubMedGoogle Scholar
  • 80 Liu X D, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice.  Cancer Res. 1998;  58 5432-5438
    PubMedGoogle Scholar
  • 81 Navarro M, Baserga R. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor.  Endocrinology. 2001;  142 1073-1081
    CrossrefPubMedGoogle Scholar
  • 82 Godar S, Horejsi V, Weidle U H, Binder B R, Hansmann C, Stockinger H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1.  Eur J Immunol. 1999;  29 1004-1013
    CrossrefPubMedGoogle Scholar
  • 83 Rochefort H. Cathepsin D in breast cancer - ia tissue marker associated with metastasis.  Eur J Cancer. 1992;  28A 1780-1783
    PubMedGoogle Scholar
  • 84 Schultz D C, Bazel S, Wright L M, Tucker S, Lange M K, Tachovsky T, Longo S, Niedbala S, Alhadeff J A. Western blotting and enzymatic activity analysis of Cathepsin-D in breast tissue and sera of patients with breast cancer and benign breast disease and of normal controls.  Cancer Res. 1994;  54 48-54
    PubMedGoogle Scholar
  • 85 Kute T E, Shao Z M, Sugg N K, Long R T, Russell G B, Case L D. Cathepsin-D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.  Cancer Res. 1992;  52 5198-5203
    PubMedGoogle Scholar
  • 86 Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency.  Oncogene. 1990;  5 1809-1814
    PubMedGoogle Scholar
  • 87 Vetvicka V, Vetvickova J, Fusek M. Effect of human procathepsin D on proliferation of human cell lines.  Cancer Lett. 1994;  79 131-135
    CrossrefPubMedGoogle Scholar
  • 88 Vetvicka V, Vetvickova J, Hilgert I, Voburka Z, Fusek M. Analysis of the interaction of procathepsin D activation peptide with breast cancer cells.  Int J Cancer. 1997;  73 403-409
    CrossrefPubMedGoogle Scholar
  • 89 de Leon D D, Issa N, Nainani S, Asmerom Y. Reversal of cathepsin D routing modulation in MCF-7 breast cancer cells expressing antisense insulin-like growth factor II (IGF-II).  Horm Metab Res. 1999;  31 142-147
    PubMedGoogle Scholar
  • 90 de Leon D D, Terry C, Asmerom Y, Nissley P. Insulin-like growth factor II modulates the routing of cathepsin D in MCF-7 breast cancer cells.  Endocrinology. 1996;  137 1851-1859
    CrossrefPubMedGoogle Scholar
  • 91 Laurent-Matha V, Farnoud M R, Lucas A, Rougeot C, Garcia M, Rochefort H. Endocytosis of pro-cathepsin D into breast cancer cells is mostly independent of mannose-6-phosphate receptors.  J Cell Sci. 1998;  111 2539-2549
    PubMedGoogle Scholar
  • 92 Glondu M, Coopman P, Laurent-Matha V, Garcia M, Rochefort H, Liaudet-Coopman E. A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells.  Oncogene. 2001;  20 6920-6929
    CrossrefPubMedGoogle Scholar
  • 93 Yang Q, Sakurai T, Kakudo K. Retinoid, retinoic acid receptor beta and breast cancer.  Br Cancer Res Treat. 2002;  76 167-173
    PubMedGoogle Scholar
  • 94 Verma A K. Retinoids in chemoprevention of cancer.  J Biol Regul Homeost Agents. 2003;  17 92-97
    PubMedGoogle Scholar
  • 95 McKenna N J, O'Malley B W. Combinatorial control of gene expression by nuclear receptors and coregulators.  Cell. 2002;  108 465-474
    CrossrefPubMedGoogle Scholar
  • 96 Chiba H, Clifford J, Metzger D, Chambon P. Specific and redundant functions of retinoid X receptor/retinoic acid receptor heterodimers in differentiation, proliferation, and apoptosis of F9 embryonal carcinoma cells.  J Cell Biol. 1997;  139 735-747
    CrossrefPubMedGoogle Scholar
  • 97 Kang J X, Li Y, Leaf A. Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid.  Proc Natl Acad Sci USA. 1997;  94 13 671-13 676
    PubMedGoogle Scholar
  • 98 Kang J X, Bell J, Beard R L, Chandraratna R A. Mannose 6-phosphate/insulin-like growth factor II receptor mediates the growth-inhibitory effects of retinoids.  Cell Growth Differ. 1999;  10 591-600
    PubMedGoogle Scholar
  • 99 Darmon A J, Bleakley R C. Proteases and cell-mediated cytotoxicity.  Crit Rev Immunol. 1998;  18 255-273
    PubMedGoogle Scholar
  • 100 Motyka B, Korbutt G, Pinkoski M J, Heibein J A, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes C FB, Gauldie J, Bleackley R C. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis.  Cell. 2000;  103 491-500
    CrossrefPubMedGoogle Scholar
  • 101 Trapani J A, Sutton V R, Thia K Y, Li Y Q, Froelich C J, Jans D A, Sandrin M S, Browne K A. A clathrin/dynamin- and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death.  J Cell Biol. 2003;  160 223-233
    CrossrefPubMedGoogle Scholar
  • 102 Nishikawa A, Gregory W, Frenz J, Cacia J, Kornfeld S. The phosphorylation of bovine DNase I Asn-linked oligosaccharides is dependent on specific lysine and arginine residues.  J Biol Chem. 1997;  272 19 408-19 412
    PubMedGoogle Scholar
  • 103 Blanchard F, Duplomb L, Raher S, Vusio P, Hoflack B, Jacques Y, Godard A. Mannose 6-phosphate/insulin-like growth factor II receptor mediates internalization and degradation of leukemia inhibitory factor but not signal transduction.  J Biol Chem. 1999;  274 24 685-24 693
    PubMedGoogle Scholar
  • 104 Playford M P, Bicknell D, Bodmer W F, Macaulay V M. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin.  Proc Natl Acad Sci USA . 2000;  97 12 103-12 108
    PubMedGoogle Scholar
  • 105 Kabir-Salmani M, Shiokawa S, Akimoto Y, Sakai K, Nagamatsu S, Nakamura Y, Lotfi A, Kawakami H, Iwashita M. AlphaVbeta3integrin signaling pathway is involved in insulin-like growth factor I-stimulated human extravillous trophoblast cell migration.  Endocrinology. 2003;  144 1620-1630
    CrossrefPubMedGoogle Scholar
  • 106 Brooks P C, Klemke R L, Schon S, Lewis J M, Schwartz M A, Cheresh D A. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo.  J Clin Invest. 1997;  99 1390-1398
    PubMedGoogle Scholar
  • 107 Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G, Marvaldi J, Luis J. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells.  Int J Cancer. 1999;  83 497-505
    CrossrefPubMedGoogle Scholar
  • 108 Minniti C P, Kohn E C, Grubb J H, Sly W S, Oh Y, Muller H L, Rosenfeld R G, Helman L J. The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells.  J Biol Chem. 1992;  267 9000-9004
    PubMedGoogle Scholar
  • 109 Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O, Antonaci S. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin.  Am J Pathol. 2002;  161 183-193
    PubMedGoogle Scholar
  • 110 Festuccia C, Bologna M, Gravina G L, Guerra F, Angelucci A, Villanova I, Millimaggi D, Teti A. Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components.  Int J Cancer. 1999;  81 395-403
    CrossrefPubMedGoogle Scholar
  • 111 Hasina R, Matsumoto K, Matsumoto-Taniura N, Kato I, Sakuda M, Nakamura T. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line.  Br J Cancer. 1999;  80 1708-1717
    CrossrefPubMedGoogle Scholar
  • 112 Mooradian D L, McCarthy J B, Komanduri K V, Furcht L T. Effects of transforming growth factor-beta 1 on human pulmonary adenocarcinoma cell adhesion, motility, and invasion in vitro.  J Natl Cancer Inst. 1992;  84 523-527
    PubMedGoogle Scholar
  • 113 Nakata D, Hamada J, Ba Y, Matsushita K, Shibata T, Hosokawa M, Moriuchi T. Enhancement of tumorigenic, metastatic and in vitro invasive capacity of rat mammary tumor cells by transforming growth factor-beta.  Cancer Lett. 2002;  175 95-106
    CrossrefPubMedGoogle Scholar
  • 114 Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via up-regulation of alpha(V)beta(3) integrin expression.  Biochem Biophys Res Commun. 2000;  268 607-611
    CrossrefPubMedGoogle Scholar
  • 115 Pilkington M F, Sims S M, Dixon S J. Transforming growth factor-beta induces osteoclast ruffling and chemotaxis: potential role in osteoclast recruitment.  J Bone Miner Res. 2001;  16 1237-1247
    PubMedGoogle Scholar
  • 116 Santibanez J F, Frontelo P, Iglesias M, Martinez J, Quintanilla M. Urokinase expression and binding activity associated with the transforming growth factor beta1-induced migratory and invasive phenotype of mouse epidermal keratinocytes.  J Cell Biochem. 1999;  74 61-73
    CrossrefPubMedGoogle Scholar
  • 117 Stahl A, Mueller B M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.  Cancer Res. 1994;  54 3066-3071
    PubMedGoogle Scholar
  • 118 Hebert C A, Baker J B. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin.  J Cell Biol. 1988;  106 1241-1247
    CrossrefPubMedGoogle Scholar
  • 119 Pollanen J, Hedman K, Nielsen L S, Dano K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.  Journal of Cell Biology. 1988;  106 87-95
    CrossrefPubMedGoogle Scholar
  • 120 Yebra M, Parry G C, Stromblad S, Mackman N, Rosenberg S, Mueller B M, Cheresh D A. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.  J Biol Chem. 1996;  271 29 393-29 399
    PubMedGoogle Scholar
  • 121 Chapman H A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration.  Curr Opin Cell Biol. 1997;  9 714-724
    CrossrefPubMedGoogle Scholar
  • 122 van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout J W, Verheijen J, Quax P, Karperien M, Papapoulos S, Lowik C. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.  Am J Pathol. 2001;  159 971-982
    PubMedGoogle Scholar
  • 123 Busso N, Masur S K, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.  J Cell Biol. 1994;  126 259-270
    CrossrefPubMedGoogle Scholar
  • 124 Duffy M J. Proteases as prognostic markers in cancer.  Clin Cancer Res. 1996;  2 613-618
    PubMedGoogle Scholar
  • 125 Foekens J A, Peters H A, Look M P, Portengen H, Schmitt M, Kramer M D, Brunner N, Janicke F, Meijer-van G elder, Henzen-Logmans S C, van Putten W L, Klijn J G. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.  Cancer Res. 2000;  60 636-643
    PubMedGoogle Scholar
  • 126 Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.  Cancer Sci. 2003;  94 43-49
    PubMedGoogle Scholar
  • 127 Duffy M J, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, Fennelly J J, O'Higgins N. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.  Enzyme Protein. 1996;  49 85-93
    PubMedGoogle Scholar
  • 128 Qian F, Bajkowski A S, Steiner D F, Chan S J, Frankfater A. Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues.  Cancer Res. 1989;  49 4870-4875
    PubMedGoogle Scholar
  • 129 Ledakis P, Tester W T, Rosenberg N, Romero-Fischmann D, Daskal I, Lah T T. Cathepsins D, B, and L in malignant human lung tissue.  Clin Cancer Res. 1996;  2 561-568
    PubMedGoogle Scholar
  • 130 Dahms N M, Lobel P, Breitmeyer J, Chirgwin J M, Kornfeld S. 46kd mannose 6-phosphate receptor: Cloning, expression, and homology to the 215kd mannose 6-phosphate receptor.  Cell. 1987;  50 181-192
    CrossrefPubMedGoogle Scholar
  • 131 Jin M, Sahagian G G Jr, Snider M D. Transport of surface mannose 6-phosphate receptor to the Golgi complex in cultured human cells.  J Biol Chem. 1989;  264 7675-7680
    PubMedGoogle Scholar
  • 132 Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor-II receptors.  Ann Rev Biochem. 1992;  61 307-330
    PubMedGoogle Scholar
  • 133 Kasper D, Dittmer F, von Figura K, Pohlmann R. Neither type of mannose 6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes.  J Cell Biol. 1996;  134 615-623
    CrossrefPubMedGoogle Scholar
  • 134 Faulhaber J, Fensom A, Hasilik A. Abnormal lysosomal sorting with an enhanced secretion of cathepsin D precursor molecules bearing monoester phosphate groups.  Eur J Cell Biol. 1998;  77 134-141
    PubMedGoogle Scholar
  • 135 Dittmer F, Hafner A, Ulbrich E J, Moritz J D, Schmidt P, Schmahl W, Pohlmann R, Figura K V. I-cell disease-like phenotype in mice deficient in mannose 6-phosphate receptors.  Transgenic Res. 1998;  7 473-483
    CrossrefPubMedGoogle Scholar
  • 136 Sohar I, Sleat D, Gong Liu C, Ludwig T, Lobel P. Mouse mutants lacking the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor are impaired in lysosomal enzyme transport: comparison of cation-independent and cation-dependent mannose 6-phosphate receptor-deficient mice.  Biochem J. 1998;  330 903-908
    PubMedGoogle Scholar
  • 137 Ludwig T, Munierlehmann H, Bauer U, Hollinshead M, Ovitt C, Lobel P, Hoflack B. Differential sorting of lysosomal enzymes in mannose 6-phosphate receptor-deficient fibroblasts.  EMBO J. 1994;  13 3430-3437
    PubMedGoogle Scholar
  • 138 Wick D A, Seetharam B, Dahms N M. Biosynthesis and secretion of the mannose 6-phosphate receptor and its ligands in polarized Caco-2 cells.  Am J Physiol. 1999;  277 G506-514
    PubMedGoogle Scholar
  • 139 O'Brien D A, Gabel C A, Eddy E M. Mouse Sertoli cells secrete mannose 6-phosphate containing glycoproteins that are endocytosed by spermatogenic cells.  Biol Reprod. 1993;  49 1055-1065
    PubMedGoogle Scholar
  • 140 Szpaderska A M, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer.  Cancer Res. 2001;  61 3493-3500
    PubMedGoogle Scholar
  • 141 Duffy M J. The role of proteolytic enzymes in cancer invasion and metastasis.  Clin Exp Metastasis. 1992;  10 145-155
    CrossrefPubMedGoogle Scholar
  • 142 Yan S, Sameni M, Sloane B F. Cathepsin B and human tumor progression.  Biol Chem. 1998;  379 113-123
    PubMedGoogle Scholar
  • 143 Mignatti P, Rifkin D B. Biology and biochemistry of proteinases in tumor invasion.  Physiol Rev. 1993;  73 161-195
    PubMedGoogle Scholar
  • 144 Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin-B.  Cancer Res. 1992;  52 3610-3614
    PubMedGoogle Scholar
  • 145 Rochefort H. Cathepsin D in breast cancer.  Breast Cancer Res Treat. 1990;  16 3-13
    CrossrefPubMedGoogle Scholar
  • 146 Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Gunzler W A, Janicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).  J Biol Chem. 1991;  266 5147-5152
    PubMedGoogle Scholar
  • 147 Andreasen P A, Kjoller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis: a review.  Int J Cancer. 1997;  72 1-22
    CrossrefPubMedGoogle Scholar
  • 148 Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?.  Trends Pharmacol Sci. 1994;  15 25-29
    CrossrefPubMedGoogle Scholar
  • 149 Plebani M, Herszenyi L, Cardin R, Roveroni G, Carraro P, Paoli M D, Rugge M, Grigioni W F, Nitti D, Naccarato R, Farinati F. Cysteine and serine proteases in gastric cancer.  Cancer. 1995;  76 367-375
    PubMedGoogle Scholar
  • 150 Ranson M, Andronicos N M, O'Mullane M J, Baker M S. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.  Br J Cancer. 1998;  77 1586-1597
    CrossrefPubMedGoogle Scholar
  • 151 Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis.  Int J Oncol. 1998;  13 893-906
    PubMedGoogle Scholar
  • 152 Duffy M J. Plasminogen activators and cancer.  Blood Coagul Fibrinolysis. 1990;  1 681-687
    PubMedGoogle Scholar
  • 153 Mohanam S, Chintala S K, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan Z L, Sawaya R, Rao J S. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.  Oncogene. 1997;  14 1351-1359
    CrossrefPubMedGoogle Scholar
  • 154 Leksa V, Godar S, Cebecauer M, Hilgert I, Breuss J, Weidle U H, Horejsi V, Binder B R, Stockinger H. The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration.  J Biol Chem. 2002;  277 40 575-40 582
    PubMedGoogle Scholar
  • 155 Kreiling J L, Byrd J C, Deisz R J, Mizukami I F, Todd R F 3rd, MacDonald R G. Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR.  J Biol Chem. 2003;  278 20 628-20 637
    PubMedGoogle Scholar
  • 156 Nykjaer A, Christensen E I, Vorum H, Hager H, Petersen C M, Roigaard H, Min H Y, Vilhardt F, Moller L B, Kornfeld S, Gliemann J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction.  Journal of Cell Biology. 1998;  141 815-828
    CrossrefPubMedGoogle Scholar
  • 157 Farina A R, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay A R. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.  Int J Cancer. 1998;  75 721-730
    CrossrefPubMedGoogle Scholar
  • 158 Capony F, Braulke T, Rougeot C, Roux S, Montcourrier P, Rochefort H. Specific mannose-6-phosphate receptor-independent sorting of pro-cathepsin D in breast cancer cells.  Exp Cell Res. 1994;  215 154-163
    CrossrefPubMedGoogle Scholar
  • 159 Dupont J, Dunn S E, Barrett J C, LeRoith D. Microarray analysis and identification of novel molecules involved in insulin-like growth factor-1 receptor signaling and gene expression.  Recent Prog Horm Res. 2003;  58 325-342
    CrossrefPubMedGoogle Scholar
  • 160 Bustin S A, Dorudi S, Phillips S M, Feakins R M, Jenkins P J. Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer.  Tumour Biol. 2002;  23 130-138
    PubMedGoogle Scholar
  • 161 Oh J S, Kucab J E, Bushel P R, Martin K, Bennett L, Collins J, DiAugustine R P, Barrett J C, Afshari C A, Dunn S E. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells.  Neoplasia. 2002;  4 204-217
    CrossrefPubMedGoogle Scholar
  • 162 Reinmuth N, Liu W, Fan F, Jung Y D, Ahmad S A, Stoeltzing O, Bucana C D, Radinsky R, Ellis L M. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer.  Clin Cancer Res. 2002;  8 3259-3269
    PubMedGoogle Scholar
  • 163 Ritter M R, Dorrell M I, Edmonds J, Friedlander S F, Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis.  Proc Natl Acad Sci USA. 2002;  99 7455-7460
    CrossrefPubMedGoogle Scholar
  • 164 Samani A A, Brodt P. The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis.  Surg Oncol Clin N Am. 2001;  10 289-312, viii
    PubMedGoogle Scholar
  • 165 Shigematsu S, Yamauchi K, Nakajima K, Iijima S, Aizawa T, Hashizume K. IGF-1 regulates migration and angiogenesis of human endothelial cells.  Endocr J. 1999;  46 S59-62
    PubMedGoogle Scholar
  • 166 Lee S-J, Nathans D. Proliferin secreted by cultured cells binds to mannose 6-phosphate receptors.  J Biol Chem. 1988;  263 3521-3527
    PubMedGoogle Scholar
  • 167 Volpert O, Jackson D, Bouck N, Linzer D. The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis.  Endocrinology. 1996;  137 3871-3876
    CrossrefPubMedGoogle Scholar
  • 168 Blancher C, Harris A L. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target.  Cancer Metastasis Rev. 1998;  17 187-194
    CrossrefPubMedGoogle Scholar
  • 169 O'Rourke J F, Dachs G U, Gleadle J M, Maxwell P H, Pugh C W, Stratford I J, Wood S M, Ratcliffe P J. Hypoxia response elements.  Oncology Res. 1997;  9 327-332
    PubMedGoogle Scholar
  • 170 Semenza G L. HIF-1 and tumor progression: pathophysiology and therapeutics.  Trends Mol Med. 2002;  8 S62-67
    CrossrefPubMedGoogle Scholar
  • 171 Harris A L. Hypoxia: A key regulatory factor in tumour growth.  Nature Rev Cancer. 2002;  2 38-47
    CrossrefPubMedGoogle Scholar
  • 172 Mazure N M, Brahimi-Horn M C, Pouyssegur J. Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis.  Curr Pharm Des. 2003;  9 531-541
    CrossrefPubMedGoogle Scholar
  • 173 Maxwell P H, Pugh C W, Ratcliffe P J. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.  Adv Exp Med Biol. 2001;  502 365-376
    PubMedGoogle Scholar
  • 174 Streeter E H, Crew J P. Angiogenesis, angiogenic factor expression and prognosis of bladder cancer.  Anticancer Res. 2001;  21 4355-4363
    PubMedGoogle Scholar
  • 175 Chavez J C, LaManna J C. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1.  J Neurosci. 2002;  22 8922-8931
    PubMedGoogle Scholar
  • 176 Fukuda R, Hirota K, Fan F, Jung Y D, Ellis L M, Semenza G L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.  J Biol Chem. 2002;  277 38 205-38 211
    PubMedGoogle Scholar
  • 177 Akeno N, Robins J, Zhang M, Czyzyk-Krzeska M F, Clemens T L. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha.  Endocrinology. 2002;  143 420-425
    CrossrefPubMedGoogle Scholar
  • 178 Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk A R, Ryan H E, Johnson R S, Jefferson A B, Stokoe D, Giaccia A J. Loss of PTEN facilitates HIF-1-mediated gene expression.  Genes Dev. 2000;  14 391-396
    PubMedGoogle Scholar
  • 179 Minet E, Michel G, Remacle J, Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis.  Int J Mol Med. 2000;  5 253-259
    PubMedGoogle Scholar
  • 180 Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza G L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.  Cancer Res. 2003;  63 1138-1143
    PubMedGoogle Scholar
  • 181 Evans C P, Elfman F, Parangi S, Conn M, Cunha G, Shuman M A. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.  Cancer Res. 1997;  57 3594-3599
    PubMedGoogle Scholar
  • 182 Pepper M S, Montesano R, Mandriota S J, Orci L, Vassalli J D. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis.  Enzyme Protein. 1996;  49 138-162
    PubMedGoogle Scholar
  • 183 Rabbani S A, Mazar A P. The role of the plasminogen activation system in angiogenesis and metastasis.  Surg Oncol Clin N Am. 2001;  10 393-415, x
    PubMedGoogle Scholar
  • 184 Lakka S S, Gondi C S, Yanamandra N, Dinh D H, Olivero W C, Gujrati M, Rao J S. Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.  Cancer Res. 2003;  63 2454-2461
    PubMedGoogle Scholar
  • 185 Le D M, Besson A, Fogg D K, Choi K S, Waisman D M, Goodyer C G, Rewcastle B, Yong V W. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.  J Neurosci. 2003;  23 4034-4043
    PubMedGoogle Scholar
  • 186 Tkachuk V, Stepanova V, Little P J, Bobik A. Regulation and role of urokinase plasminogen activator in vascular remodelling.  Clin Exp Pharmacol Physiol. 1996;  23 759-765
    CrossrefPubMedGoogle Scholar

C. Scott

Growth Research Unit · Kolling Institute of Medical Research · Royal North Shore Hospital

Reserve Rd · St Leonards · NSW 2065 · Australia

Phone: +612(9926)8486

Fax: +612(9926)8484

Email: cscott@med.usyd.edu.au

      >